|drug3490||Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 Wiki||1.00|
|drug3491||Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared to SOC alone.
Description: The primary endpoint will be the disease severity on the 7-point WHO Ordinal Scale on day 7. This endpoint has been suggested by WHO for clinical trials in patients with COVID-19Measure: Disease Severity on the 7-Point WHO Ordinal Scale Time: Assessed on each day after enrollment (worst status) with the use of the WHO Ordinal Scale and the score on day 7 will be analyzed stratified by its baseline value
Description: at least 2 points Ordinal Scale for Clinical Improvement, clinical severity will be assessed.Measure: Clinical improvement Time: Daily until day 14
Description: Admission to ICU with invasive or non-invasive ventilation or death will be assessed.Measure: Invasive or non-invasive ventilation Time: Daily until day 14.
Description: Patients with ALI within 14 days after enrollment, PaO2/FiO2 will be determined daily. This is only relevant for patients with arterial blood gas sampling performed in the ICU or rarely in the medical unit.Measure: Acute Lung Injury Time: Daily until day 14.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports